Announcement PDF ABN 16 165 160 841 ASX RELEASE 10 January 2025 Release of Shares from Voluntary Escrow Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) confirms in accordance with ASX Listing Rule 3.10A that 781,250 ordinary shares issued on 19 July 2024 as a fee for services of a corporate advisor will be released from voluntary escrow on 19 January 2025. This ASX announcement is authorised for release by the Company Secretary. - End Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com